Wisniewski Alex M, Suzuki Yota, El Moheb Mohamad, Chipoletti Ashley, Strobel Raymond J, Norman Anthony V, Lynch William, Chatterjee Subhasis, Loor Gabriel, Teman Nicholas R, Carrott Philip
Division of Cardiothoracic Surgery, University of Virginia, Charlottesville, Virginia.
Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ann Thorac Surg. 2024 Dec 24. doi: 10.1016/j.athoracsur.2024.12.011.
Donor stagnation and modification of lung allocation scores has resulted in a higher acuity of patient presentation before lung transplantation. Extracorporeal membrane oxygenation (ECMO) has been used as a bridge to lung transplant (BTT), although the effect of cannulation strategy on outcomes has not been well investigated. We analyzed contemporary data on ECMO BTT by using a large, international registry of patients.
We used the Extracorporeal Life Support Organization registry to identify all adult patients from 2010 to 2022 undergoing ECMO as a BTT. Patients were stratified by venovenous or venoarterial support type.
A total of 1066 patients were identified. ECMO BTT increased over the study period (P < .001), as did survival to hospital discharge (P < .001), with an overall survival of 87.7%. Venovenous patients experienced fewer complications on ECMO, including dialysis (16.7% vs 25.3%, P = .006), stroke (1.4% vs 5.1%, P = .004), and limb ischemia (0.2% vs 3.4%, P < .001) and required ECMO less frequently in the postoperative period (41.0% vs 53.4%, P = .002) and for less time (4 days [interquartile range, 2-7 days] vs 5 days [interquartile range, 3-9 days], P = .01). In-hospital mortality was significantly lower for venovenous patients compared with venoarterial patients (11.0% vs 18.5%, P = .005). Increasing center volume of ECMO BTT was protective of in-hospital mortality (P < .001), with benefit observed after ∼45 total BTT intent cannulations.
ECMO BTT has resulted in improved posttransplant survival to discharge. Owing to a higher rate of complications and worsened mortality, thoughtful implementation of venoarterial ECMO in BTT should be undertaken when assessing patient candidacy.
供体器官停滞以及肺分配评分的调整导致肺移植前患者的病情严重程度增加。体外膜肺氧合(ECMO)已被用作肺移植(BTT)的过渡手段,尽管插管策略对预后的影响尚未得到充分研究。我们通过一个大型国际患者登记系统分析了关于ECMO辅助BTT的当代数据。
我们使用体外生命支持组织登记系统来识别2010年至2022年期间所有接受ECMO作为BTT的成年患者。患者按静脉-静脉或静脉-动脉支持类型进行分层。
共识别出1066例患者。在研究期间,ECMO辅助BTT的病例数增加(P <.001),出院生存率也增加(P <.001),总体生存率为87.7%。静脉-静脉支持的患者在接受ECMO治疗时出现的并发症较少,包括透析(16.7%对25.3%,P =.006)、中风(1.4%对5.1%,P =.004)和肢体缺血(0.2%对3.4%,P <.001),并且术后需要ECMO的频率较低(41.0%对53.4%,P =.002),使用时间也较短(4天[四分位间距,2 - 7天]对5天[四分位间距,3 - 9天],P =.01)。与静脉-动脉支持的患者相比,静脉-静脉支持的患者住院死亡率显著更低(11.0%对18.5%,P =.005)。ECMO辅助BTT中心病例数的增加对住院死亡率具有保护作用(P <.001),在总共约45例BTT意向插管后观察到益处。
ECMO辅助BTT提高了移植后出院生存率。由于并发症发生率较高且死亡率恶化,在评估患者是否适合时,应谨慎实施静脉-动脉ECMO用于BTT。